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randomised trials: RAVEL (largely patients with narrow vessels),
and E-SIRIUS and SIRIUS (largely patients with long lesions).
Resource costs of the initial procedures and all subsequent events
were taken from NHS Reference Costs; manufacturers’ list prices
were used for the devices. A utility decrement, based on EQ-5D
data collected in an earlier stent trial, was included for further
revascularisation based on the expected duration of symptoms
prior to re-treatment. Cost-effectiveness is reported in terms of
the incremental cost per additional QALY, and cost-effectiveness
acceptability curves are reported showing the probability of DES
being the more cost-effective at particular threshold values for
an additional QALY. RESULTS: Based on clinical data from
RAVEL the cost per QALY was £30,400. The corresponding
results for SIRIUS and E-SIRIUS were £10,500 and £4,950,
respectively. Sensitivity analysis showed that when the clinically
similar mortality rates observed in the trials were incorpo-
rated into the model, they had a major impact on mean cost-
effectiveness but increased uncertainty. CONCLUSIONS: The
incremental cost per QALY of DES, relative to bare metal stent,
was consistently below £35,000 for all sub-groups. There was
considerable uncertainty surrounding cost-effectiveness suggest-
ing additional research may be appropriate.
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LOWER CARDIOVASCULAR RISK ASSOCIATED WITH
PIOGLITAZONE MONOTHERAPY COMPARED TO INSULIN
MONOTHERAPY: A RETROSPECTIVE PROPENSITY SCORE
MATCHED COHORT STUDY
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OBJECTIVE: To investigate the cardiovascular risk associ-
ated with pioglitazone monotherapy as compared to insulin
monotherapy in a large retrospective database. METHOD:
Patients ≥ 18 years of age with a diagnosis of type-2 diabetes
and initiated with pioglitazone or insulin monotherapy for at
least 6 months with no cardiovascular events reported at base-
line were selected from GE Medical Systems (GEMS) database
of electronic medical records from physician ofﬁces. Patients pre-
scribed other oral anti-diabetic drugs were excluded. Cardiovas-
cular events included one or more of the following forms of
coronary artery disease: myocardial infarction, angina pectoris,
unstable angina, other ischemic heart disease and surgical pro-
cedures of coronary artery bypass and angioplasty, and conges-
tive heart failure. To avoid selection bias, patients were matched
1 :1 on pioglitazone and insulin using propensity scores. Base-
line demographics and clinical characteristics such as duration
of disease, co-morbidities, medical therapies, and duration of
treatment were included in the propensity score analysis. Logis-
tic regression was used to calculate the odds ratio of the cardio-
vascular event in the follow-up period with treatment as the
factor and signiﬁcant (p < 0.1) baseline characteristics as the
adjusting covariates in the model. RESULTS: A total of 381
patients on pioglitazone monotherapy were compared with an
equal number of patients on insulin monotherapy. The crude car-
diovascular event rate in the pioglitazone group was 1.84% com-
pared with 9.71% in the insulin group (p < 0.001). The hazard
ratio was 0.174 for pioglitazone (95% CI = 0.077, 0.396; p <
0.001). The signiﬁcant risk reduction projected for the pioglita-
zone group could not be completely explained by baseline labo-
ratory measurements of lipids, serum creatinine, systolic and
diastolic blood pressure, or duration of diabetes. CONCLU-
SION: In a retrospective propensity-matched cohort analysis in
patients with type-2 diabetes, patients treated with pioglitazone
monotherapy had a signiﬁcantly lower incidence of cardiovas-
cular events than those taking insulin monotherapy.
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OBJECTIVE: To assess the state of the science of HRQOL
assessment in cancer. METHODS: The US National Cancer
Institute formed the Cancer Outcomes Measurement Working
Group (COMWG) made up of 35 leading experts in the ﬁeld to
review the state of the science of assessing three outcomes
(HRQOL, patient satisfaction, economic burden) in four cancers
(breast, prostate, lung, colorectal) across the continuum of care
(screening/prevention, treatment, survivorship, end of life). In
this presentation, the ﬁndings of the COMWG are evaluated
using the Medical Outcomes Trust Instrument Review Criteria.
RESULTS: The results are as follows: 1) There is currently no
consensus deﬁnition or conceptual model for HRQOL; deve-
loping a stronger theoretical base would improve HRQOL 
measurement and interpretation; 2) While there are now 
well-validated HRQOL instruments, validity can be further
enhanced by an integrated application of the tools from modern
psychometrics—especially item response theory (IRT) model-
ing—survey research, and cognitive psychology; 3) a number of
instruments demonstrate adequate internal reliability according
to classical test theory, but reliability could be evaluated more
precisely at different points along the HRQOL continuum using
IRT approaches; 4) interpretation of HRQOL ﬁndings has ben-
eﬁted from recent research on deﬁning and identifying clinically
important differences in instrument scores; both anchor-based
and distribution-based approaches suggest changes of about 7%
of a scale’s breadth are important to patients and clinicians; 5)
responsiveness of a measure is demonstrated when it is shown
to detect statistically signiﬁcant differences in HRQOL also large
enough to be clinically important; 6) while current measurement
techniques have generally proven feasible and acceptable, IRT-
based computer adaptive testing may signiﬁcantly decrease
respondent burden without sacriﬁcing precision; and 7) for
cross-cultural assessment of HRQOL, several instruments cur-
rently meet minimum criteria. CONCLUSIONS: The current
state of the science of HRQOL assessment in cancer is strong.
Further development of a theoretical base and use of modern
analytic techniques, including IRT, will accelerate progress.
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OBJECTIVES: Given the dramatic increase in the incidence of
melanoma worldwide, accurate assessment of the economic
value of staging and treatment options for melanoma is critically
needed to guide policy making. METHODS: Cost-effectiveness
(CE) evaluations published between 1990 and 2003 of diagnos-
tic procedures and treatments of melanoma were identiﬁed via
systematic searches of MEDLINE® and conference proceedings.
Costs and CE ratios presented in each study were updated to
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2001 U.S. dollars, then compared and contrasted. RESULTS:
Thirty studies were identiﬁed and reviewed. Seventeen assessed
diagnostic modalities: education and screening (6): dissection
and biopsy (3), follow-up/monitoring (2), chest X-ray (3), CT
and PET scan (3), while 13 evaluated treatments: surgery 
(3), adjuvant interferon (IFN-a) (9), and chemotherapy (1).
Melanoma education and screening programs appears to be cost-
saving or to have CE ratios <$50,000 per QALY saved. Of the
diagnostic, monitoring, and risk stratiﬁcation methods, physical
examination appears more cost-effective than chest x-rays,
abdominal ultrasound, CT scans, PET scans, and liver function
tests. The CE of therapeutic options depends on disease stage,
comorbidity, and other factors. All nine IFN-a studies across
multiple countries and research designs consistently present
favorable CE ratios, which improve as study time horizon is
extended. Among other therapies, Mohs micrographic surgery
appears more cost-effective than surgical excision and resection.
Radiosurgery combined with radiotherapy also appears to be
cost-effective compared to radiotherapy alone in at least some
subset of patients. Finally, the CE of experimental treatment such
as isolated limb perfusion, vaccines, and gene therapies, has not
been studied. CONCLUSIONS: The literature provides valuable
information to policy makers seeking to reduce the economic
burden of melanoma, most notably with respect to physical
examination and interferon. As new diagnostic and therapeutic
modalities become available, research is needed on their eco-
nomic value.
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OBJECTIVES: Results from the ATAC trial indicated that anas-
trozole was superior to tamoxifen in terms of disease free sur-
vival in the adjuvant treatment of postmenopausal women with
hormone receptor-positive (HR+) EBC. Using updated 47-month
data (Cancer 2003;98:1802–10), we calculated the direct
medical costs and incremental cost effectiveness ratio (ICER) per
life year gained (LYG) for managing this group for anastrozole
compared with tamoxifen within the UK NHS setting.
METHODS: Using the updated ATAC data, we developed a
probabilistic Markov model, which projected outcomes for both
anastrozole and tamoxifen to 25 years (lifetime horizon) by
extrapolating pooled Kaplan-Meier curves. General mortality
data were obtained from UK national statistics. It was assumed
that anastrozole and tamoxifen would be given for ﬁve years
maximum and that recurrence rates after this treatment period
would be equivalent in the two groups—a conservative
approach. Resource utilization data associated with treating
adverse events were obtained from published literature. Other
resource utilization data were estimated from interviews with six
UK physicians. Unit costs in GBP were obtained from 2002 NHS
reference costs and 2003 drug costs (BNF). Costs and beneﬁts
were discounted at 6% and 1.5%, respectively. RESULTS: Con-
sidering a cohort of 1000 patients modeled for 25 years, anas-
trozole was estimated to lead to 184 discounted LYG at an
additional cost of £2.1 million. Consequently, the discounted
ICER of anastrozole compared with tamoxifen was estimated to
be £11,747/LYG (95% CI £1,946–£21,984). Furthermore,
acceptability curves showed that the estimated cost/LYG at 25
years was <£20,000 with a probability >90%. The result com-
pared favorably with commonly accepted thresholds for cost-
effectiveness of other cancer drugs and was robust to all para-
meters (including adverse events) tested in sensitivity analyses.
CONCLUSIONS: Based on these ﬁndings, anastrozole should be
a cost-effective alternative to tamoxifen for the adjuvant treat-
ment of postmenopausal women with HR+ early breast cancer.
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OBJECTIVES: We examined the cost-effectiveness (CE) of treat-
ment with adjuvant high-dose Interferon-alpha (IFN-alpha)
given in melanoma patients at high-risk for recurrence from a
program perspective. METHODS: A continuous-time Markov
model with nine health states (no evidence of disease, local-
regional recurrence, ﬁrst salvage local-regional recurrence,
second local-regional recurrence, ﬁrst distant recurrence, sal-
vaged distant recurrence, second distant recurrence, death from
melanoma, and death of other causes) was designed to assess the
CE of IFN-alpha treatment compared to no adjuvant treatment.
Estimates of costs (inﬂated to 2002), utilities for health states,
and treatment beneﬁts were retrieved from published literature.
A non-informative prior was used for the survival parameters
and patient-level data was simulated with survival parameters
retrieved from published literature. To quantify the tradeoff
between IFN-alpha toxicity and survival, net beneﬁts were 
calculated as potential savings in quality-adjusted life years
(QALYs). Average costs and beneﬁts were derived from the inte-
gration over unknown patient parameters. The posterior incre-
mental cost-effectiveness ratio (ICER) was then simulated as the
difference in average cost divided by the difference in average
effectiveness. RESULTS: The posterior mean estimate of the
incremental costs of the IFN-alpha was $37,000 and the poste-
rior mean estimate of the incremental beneﬁts was 0.75 QALY.
The estimated posterior mean ICER was $50,300/QALY with
standard deviation $183/QALY. The acceptability curve (CEAcc)
shows that the probability that IFN-alpha treatment will lead to
improved life expectancy is one. CONCLUSIONS: IFN-alpha
treatment is more costly and more effective based on simulated
patient-level data. With patient-level data, we will be able to
provide information on the variability of model parameters and
produce the acceptability curve using the current model.
RESPIRATORY DISORDERS AND INFECTIONS
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THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE
COST OF CARE FOR MEDICARE BENEFICIARIES WITH
ASTHMA
Atherly A,Williams S, Redd S
Centers for Disease Control, Atlanta, GA, USA
OBJECTIVE: To investigate the cost of asthma care for enrollees
in the Medicare program and the effect of voluntary outpatient
prescription drug coverage on Medicare covered asthma expen-
ditures. METHODS: Data were drawn from the 2001 Medicare
Current Beneﬁciary Survey, a nationally representative sample of
the Medicare population, which includes data on health care
expenditures and individual characteristics such as health status.
Sample size was 13,998, including 1,310 persons with asthma.
We used regression analysis to examine differences in expendi-
tures between those with and without asthma, controlling for
other chronic illnesses, self-rated health, age, gender, activity of
